{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:33:32Z","timestamp":1784878412191,"version":"3.55.0"},"reference-count":24,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The prospective, multicenter, double-blind study presented in this report evaluated whether or not intravenous (IV) administration of doripenem, a carbapenem with bactericidal activity against gram-negative and gram-positive uropathogens, is inferior to IV administration of levofloxacin in the treatment of complicated urinary tract infection (cUTI). Patients (\n            <jats:italic>n<\/jats:italic>\n            = 753) with complicated lower UTI or pyelonephritis were randomly assigned to receive IV doripenem at 500 mg every 8 h (q8h) or IV levofloxacin at 250 mg q24h. Patients in both treatment arms were eligible to switch to oral levofloxacin after 3 days of IV therapy to complete a 10-day treatment course if they demonstrated significant clinical and microbiological improvements. The microbiological cure rate (primary end point) was determined at the test-of-cure (TOC) visit occurring 5 to 11 days after the last dose of antibiotic. For the microbiologically evaluable patients (\n            <jats:italic>n<\/jats:italic>\n            = 545), the microbiological cure rates were 82.1% and 83.4% for doripenem and levofloxacin, respectively (95% confidence interval [CI] for the difference, \u22128.0 to 5.5%); in the microbiological modified intent-to-treat cohort (\n            <jats:italic>n<\/jats:italic>\n            = 648), the cure rates were 79.2% and 78.2%, respectively. Clinical cure rates at the TOC visit were 95.1% in the doripenem arm and 90.2% in the levofloxacin arm (95% CI around the difference in cure rates [doripenem cure rate minus levofloxacin cure rate], 0.2% to 9.6%). Both treatment regimens were generally well tolerated. Doripenem was found not to be inferior to levofloxacin in terms of therapeutics and is now approved for use in the United States and Europe for the treatment of adults with cUTI, including pyelonephritis. As fluoroquinolone resistance increases, doripenem may become a more important option for successful treatment of cUTIs, including treatment of pyelonephritis.\n          <\/jats:p>","DOI":"10.1128\/aac.00837-08","type":"journal-article","created":{"date-parts":[[2009,7,7]],"date-time":"2009-07-07T01:46:04Z","timestamp":1246931164000},"page":"3782-3792","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":67,"title":["Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis"],"prefix":"10.1128","volume":"53","author":[{"given":"K. G.","family":"Naber","sequence":"first","affiliation":[{"name":"Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Llorens","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kaniga","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kotey","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hedrich","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Redman","sequence":"additional","affiliation":[{"name":"Johnson &amp; Johnson Pharmaceutical Research &amp; Development, Raritan, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki344"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01054-9"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2005.01271.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.4.1384-1396.2004"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.tox.2006.02.004","volume":"222","year":"2006","unstructured":"Horiuchi, M., M. Kimura, M. Tokumura, N. Hasebe, T. Arai, and K. Abe. 2006. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology222:114-124.","journal-title":"Toxicology"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0090-4295(02)01664-3","volume":"60","year":"2002","unstructured":"Jimenez-Cruz, F., A. Jasovich, J. Cajigas, Q. Jiang, D. Imbeault, G. L. Woods, R. M. Gesser, and the Protocol 021 Study Group. 2002. A prospective, multicenter, randomized, double-blind study comparing ertapenem and ceftriaxone followed by appropriate oral therapy for complicated urinary tract infections in adults. Urology60:16-22.","journal-title":"Urology"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(01)00287-5"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3136-3140.2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh298"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2004.12.008"},{"key":"e_1_3_2_12_2","first-page":"S127","volume":"10","year":"2006","unstructured":"Jones, R. N., M. G. Stillwell, H. S. Sader, and T. R. Fritsche. 2006. Uniformly enhanced activity of doripenem compared to other carbapenems (imipenem, meropenem) when testing P. aeruginosa isolates: results from three continents. Int. J. Infect. Dis.10(Suppl. 1):S127-S128.","journal-title":"Int. J. Infect. Dis."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1345\/aph.1H396","volume":"40","year":"2006","unstructured":"Kahan, N. R., D. P. Chinitz, D. A. Waitman, D. Dushnitzky, E. Kahan, and M. Shapiro. 2006. Empiric treatment of uncomplicated urinary tract infection with fluoroquinolones in older women in Israel: another lost treatment option? Ann. Pharmacother.40:2223-2227.","journal-title":"Ann. Pharmacother."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijantimicag.2006.05.009","volume":"28","year":"2006","unstructured":"Muratani, T., and T. Matsumoto. 2006. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae. Int. J. Antimicrob. Agents28(Suppl. 1):S10-S13.","journal-title":"Int. J. Antimicrob. Agents"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3086-3092.2004"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00002018-199615020-00001","volume":"15","year":"1996","unstructured":"Norrby, S. R. 1996. Neurotoxicity of carbapenem antibacterials. Drug Saf.15:87-90.","journal-title":"Drug Saf."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.diagmicrobio.2005.10.010","volume":"54","year":"2006","unstructured":"Rhomberg, P. R., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2006. Clonal occurrences of multidrug-resistant Gram-negative bacilli: report from the Meropenem Yearly Susceptibility Test Information Collection surveillance program in the United States (2004). Diagn. Microbiol. Infect. Dis.54:249-257.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2006.07.009"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.5.1402-1406.2001"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/ja.2006.31","volume":"59","year":"2006","unstructured":"Sakyo, S., H. Tomita, K. Tanimoto, S. Fujimoto, and Y. Ike. 2006. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa. The high potency of a new carbapenem doripenem. J. Antibiot.59:220-228.","journal-title":"J. Antibiot."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"45S","DOI":"10.1016\/S0002-9343(02)01059-8","volume":"113","year":"2002","unstructured":"Schaeffer, A. J. 2002. The expanding role of fluoroquinolones. Am. J. Med.113(Suppl. 1A):45S-54S.","journal-title":"Am. J. Med."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.9.2895-2900.2002"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.eururo.2005.12.017","volume":"49","year":"2006","unstructured":"Wagenlehner, F. M. E., and K. G. Naber. 2006. Treatment of bacterial urinary tract infections: presence and future. Eur. Urol.49:235-244.","journal-title":"Eur. Urol."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhin.2004.12.017","volume":"60","year":"2005","unstructured":"Wagenlehner, F. M. E., W. Weidner, and K. G. Naber. 2005. Emergence of antibiotic resistance amongst hospital-acquired urinary tract infections and pharmacokinetic\/pharmacodynamic considerations. J. Hosp. Infect.60:191-200.","journal-title":"J. Hosp. Infect."},{"key":"e_1_3_2_25_2","first-page":"469","volume":"27","year":"2006","unstructured":"Zhanel, G. G., T. L. Hisanaga, N. M. Laing, M. R. DeCorby, K. A. Nichol, B. Weshnoweski, J. Johnson, A. Noreddin, D. E. Low, J. A. Karlowsky, and D. J. Hoban. 2006. Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaboration Alliance (NAUTICA). Int. J. Antimicrob. Agents27:469-475.","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00837-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00837-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:53:58Z","timestamp":1645473238000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00837-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["10.1128\/AAC.00837-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00837-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9]]},"assertion":[{"value":"2008-06-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-06-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}